Li Grace Xiaoying, Sebaratnam Deshan Frank
Faculty of Medicine and Health, University of New South Wales, Kensington, New South Wales, Australia.
Department of Dermatology, Liverpool Hospital, Liverpool, New South Wales, Australia.
Australas J Dermatol. 2024 Dec;65(8):e259-e262. doi: 10.1111/ajd.14369. Epub 2024 Oct 4.
Sirolimus is being increasingly employed to manage specific vascular anomalies. We performed an exploratory cost-utility analysis to evaluate sirolimus as a treatment for vascular malformations from the Australian healthcare system perspective. Over a one-year time horizon, sirolimus treatment was associated with an increased expenditure of AU$2832.80 and a gain of 0.08 quality-adjusted life years (QALYs) when compared to supportive care, resulting in an incremental cost-effectiveness ratio of AU$35,410/QALY. By most metrics, sirolimus would be considered a cost-effective treatment for vascular malformations.
西罗莫司越来越多地被用于治疗特定的血管异常。我们进行了一项探索性成本效用分析，从澳大利亚医疗保健系统的角度评估西罗莫司作为血管畸形治疗方法的效果。在一年的时间范围内，与支持性治疗相比，西罗莫司治疗导致支出增加2832.80澳元，质量调整生命年（QALY）增加0.08，增量成本效益比为35410澳元/QALY。根据大多数指标，西罗莫司可被视为治疗血管畸形的具有成本效益的疗法。
